Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study
Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study
Aromatase inhibitor (AI)-associated arthralgia limits adherence to therapy in breast cancer. The pathophysiology may involve vitamin D status. We wished to establish the optimal concentration of 25(OH)D that prevents or minimizes arthralgia. We used a prospective cohort of 290 women starting AI in whom baseline vitamin D was measured. All received daily vitamin D3 (800 IU) with calcium. Women with baseline 25(OH)D concentration <30 ng/ml also received 16,000 IU of D3 orally every 2 weeks. The primary outcome was incident or worsening joint pain derived from baseline and 3-month visual analogic scale (VAS) for joint pain. Regression models were used to analyse the association between vitamin D concentrations at 3 months and pain adjusting for age, BMI, season when the sample was drawn, aromatase inhibitor (exemestane vs. letrozole/anastrozole), prior tamoxifen therapy, baseline NTX, and previous fracture. 90% of women had a 25(OH)D <30 ng/ml at baseline. After supplementation (daily 800 IU and additional 16,000 IU every 2 weeks), 50% of them still failed to reach adequate concentrations at 3 months. In the whole cohort, there was an increase in joint pain (mean 1.16 points SD 2.66; P < 0.001) and the increase was significantly (P = 0.02) attenuated in those that reached concentrations of 25(OH)D of ?40 ng/ml, with a lower risk of incident arthralgia (OR 0.12 ** [0.03 to 0.40]). A target concentration of 40 ng/ml 25OHD may prevent development of AI arthralgia but higher loading doses are required to attain this level in women with deficiency at baseline.
869-878
Prieto-Alhambra, D.
19a5643f-5969-4c0e-b6a9-863fb9e9d1c7
Javaid, M.K.
51d3310b-032e-4c15-83ac-b878bce090f3
Servitja, S.
90681870-f898-42dd-8d1c-ffa8f200fe91
Arden, N.
23af958d-835c-4d79-be54-4bbe4c68077f
Martinez-Garcia, M.
d51564c3-2f9f-4824-9299-040958d68705
Diez-Perez, A.
19f89c53-003a-469c-92ac-69b0b979f3ec
Albanell, J.
128f57e7-b48e-4fb4-ac13-56f952418f78
Tusquets, X.
e29e4b31-1da7-4c90-a3fe-ef823a6ee249
February 2011
Prieto-Alhambra, D.
19a5643f-5969-4c0e-b6a9-863fb9e9d1c7
Javaid, M.K.
51d3310b-032e-4c15-83ac-b878bce090f3
Servitja, S.
90681870-f898-42dd-8d1c-ffa8f200fe91
Arden, N.
23af958d-835c-4d79-be54-4bbe4c68077f
Martinez-Garcia, M.
d51564c3-2f9f-4824-9299-040958d68705
Diez-Perez, A.
19f89c53-003a-469c-92ac-69b0b979f3ec
Albanell, J.
128f57e7-b48e-4fb4-ac13-56f952418f78
Tusquets, X.
e29e4b31-1da7-4c90-a3fe-ef823a6ee249
Prieto-Alhambra, D., Javaid, M.K., Servitja, S., Arden, N., Martinez-Garcia, M., Diez-Perez, A., Albanell, J. and Tusquets, X.
(2011)
Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study.
Breast Cancer Research and Treatment, 125 (3), .
(doi:10.1007/s10549-010-1075-9).
(PMID:20665105)
Abstract
Aromatase inhibitor (AI)-associated arthralgia limits adherence to therapy in breast cancer. The pathophysiology may involve vitamin D status. We wished to establish the optimal concentration of 25(OH)D that prevents or minimizes arthralgia. We used a prospective cohort of 290 women starting AI in whom baseline vitamin D was measured. All received daily vitamin D3 (800 IU) with calcium. Women with baseline 25(OH)D concentration <30 ng/ml also received 16,000 IU of D3 orally every 2 weeks. The primary outcome was incident or worsening joint pain derived from baseline and 3-month visual analogic scale (VAS) for joint pain. Regression models were used to analyse the association between vitamin D concentrations at 3 months and pain adjusting for age, BMI, season when the sample was drawn, aromatase inhibitor (exemestane vs. letrozole/anastrozole), prior tamoxifen therapy, baseline NTX, and previous fracture. 90% of women had a 25(OH)D <30 ng/ml at baseline. After supplementation (daily 800 IU and additional 16,000 IU every 2 weeks), 50% of them still failed to reach adequate concentrations at 3 months. In the whole cohort, there was an increase in joint pain (mean 1.16 points SD 2.66; P < 0.001) and the increase was significantly (P = 0.02) attenuated in those that reached concentrations of 25(OH)D of ?40 ng/ml, with a lower risk of incident arthralgia (OR 0.12 ** [0.03 to 0.40]). A target concentration of 40 ng/ml 25OHD may prevent development of AI arthralgia but higher loading doses are required to attain this level in women with deficiency at baseline.
This record has no associated files available for download.
More information
Published date: February 2011
Identifiers
Local EPrints ID: 172881
URI: http://eprints.soton.ac.uk/id/eprint/172881
ISSN: 0167-6806
PURE UUID: 83646f53-ecf5-45e5-9c04-9c01c9a43bf2
Catalogue record
Date deposited: 31 Jan 2011 15:02
Last modified: 14 Mar 2024 02:30
Export record
Altmetrics
Contributors
Author:
D. Prieto-Alhambra
Author:
M.K. Javaid
Author:
S. Servitja
Author:
M. Martinez-Garcia
Author:
A. Diez-Perez
Author:
J. Albanell
Author:
X. Tusquets
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics